INCH

Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics in oncology, hematology, and inflammation and autoimmunity. The company is best known for its lead product, Jakafi (ruxolitinib), which is approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. Incyte's portfolio also includes Opzelura (ruxolitinib cream) for atopic dermatitis and vitiligo, as well as Pemazyre for cholangiocarcinoma. With a robust pipeline of small molecules and monoclonal antibodies, Incyte continues to expand its presence in precision medicine and targeted therapies. The company maintains significant partnerships with major pharmaceutical firms like Novartis and Eli Lilly to co-develop and commercialize its innovative candidates.